Update on Applied Therapeutics' FDA Discussion
Applied Therapeutics, Inc. (NASDAQ: APLT), a dedicated biopharmaceutical company, has taken significant steps in its quest to bring innovative treatments for rare diseases to market. Recently, the company announced the completion of a crucial meeting with the U.S. Food and Drug Administration (FDA), focusing on the potential submission for a new drug application (NDA) related to the lead drug candidate, govorestat. This drug is aimed at treating Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency.
Current Status of NDA Submission
While the meeting marked an essential milestone, the company is currently awaiting the FDA's official meeting minutes, which will outline the key points discussed. The absence of a definitive submission strategy signals a continued evaluation of pathways for regulatory approval, including alternative routes like accelerated approval.
Understanding CMT-SORD
Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency is a rare and progressive hereditary neuropathy that notably impacts peripheral nerves. According to estimates, it affects approximately 3,300 patients in the U.S. and around 4,000 patients across Europe. The underlying cause of CMT-SORD is linked to a deficiency of the enzyme sorbitol dehydrogenase—a crucial component in sorbitol metabolism. Without adequate levels of this enzyme, sorbitol can accumulate, leading to significant health challenges such as sensory loss, neuromuscular dysfunction, and decreased mobility.
Govorestat: A Potential Breakthrough
Govorestat, also known as AT-007, is an innovative Aldose Reductase Inhibitor designed to penetrate the central nervous system (CNS). This drug is not only being explored for CMT-SORD but also for other rare conditions like Classic Galactosemia and PMM2 congenital disorder of glycosylation. Its unique mechanism represents a promising strategy in the fight against these debilitating diseases.
Regulatory Designations for Govorestat
Govorestat has received special designations from both the European Medicines Agency (EMA) and the U.S. FDA. This includes Orphan Medicinal Product Designation for CMT-SORD and Galactosemia, as well as Orphan Drug Designation for multiple conditions. Additionally, it has been awarded Rare Pediatric Disease designation and Fast Track designation in the U.S., further illustrating its potential impact in rare disease treatment.
About Applied Therapeutics
Applied Therapeutics is deeply committed to developing novel therapies that address the unmet medical needs of patients with rare diseases. Their approach focuses on validated molecular targets, aiming to bring hope and improved health outcomes to patients suffering from these conditions. With govorestat as the lead candidate, the company aims to deliver transformative healthcare solutions by leveraging cutting-edge research and development.
Contact Information
Investors:
Julie Seidel / Andrew Vulis
(212) 600-1902
Email: appliedtherapeutics@argotpartners.com
Media:
Email: media@appliedtherapeutics.com
Frequently Asked Questions
What is the latest update from Applied Therapeutics regarding the FDA?
Applied Therapeutics announced the completion of a meeting with the FDA to discuss the NDA submission for their drug, govorestat.
What is govorestat designed to treat?
Govorestat is being developed to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency, Classic Galactosemia, and PMM2-CDG.
Why is govorestat significant?
This drug represents a potential breakthrough in treating rare diseases affecting the central nervous system and offers new hope for affected individuals.
What designations has govorestat received?
Govorestat has received Orphan Drug Designation and other status from regulatory bodies that highlight its importance in rare disease treatment.
How can I learn more about the company?
You can visit Applied Therapeutics' official website for more information on their research, developments, and news updates.
